Merck's Capvaxive Vaccine Wins US Approval for High-Risk Children, Teens
MRK sits 51% above its 52-week low of $76.66.
Summary
The US FDA has approved Merck's pneumococcal vaccine, Capvaxive, for expanded use in high-risk children and teenagers aged 2-17. This approval targets patients with chronic conditions like heart, lung, kidney, liver disease, or diabetes, who are at increased risk of serious infections. This expands the market for Capvaxive, which was initially approved for adults in June 2024, adding to Merck's robust vaccine portfolio and contributing to future revenue streams.
At the time of this announcement, MRK was trading at $115.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $285.1B. The 52-week trading range was $76.66 to $125.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.